FPFariba Pourkarim

Fariba Pourkarim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fariba Pourkarim has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molnupiravir: A new candidate for COVID-19 treatment

    by Fariba Pourkarim, Samira Pourtaghi-Anvarian, Haleh Rezaee

    The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action of molnupiravir in COVID-19, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients.

  • Open Access

    All available clinical data on anakinra in COVID-19: an updated comprehensive review

    by Marzieh Shahrabi, Elnaz Khani, Fariba Pourkarim, Hoda Afsharirad, Mohammad Solduzian

    Background: Based on the investigations, cytokine-release syndrome (CRS) play a key role in the development of acute respiratory distress syndrome (ARDS) following SARS-CoV-2 infection. Anakinra can be effective in the management of CRS by inhibiting IL-1 from binding to the interleukin-1 receptors. We aimed to review the current clinical evidence regarding the therapeutic effects of anakinra in the management of ARDS in the context of the coronavirus disease 2019 (COVID-19). Methods: PubMed and google scholar databases were searched and all of the case reports, case series and RCTs were reviewed. Also, we searched www.clinicaltrial.gov database for ongoing clinical trials of anakinra. Results: Overall, 31 articles were found, and included 9 case report, 6 case-series and 11 RCTs. One of the reports of RCTs was not peer reviewed. Also, ten ongoing studies were found in the clinicaltrial.gov database searching. Conclusion: Four items have been shown to be important to achieve the optimal therapeutic effect of anakinra in patients withCOVID-19. These items include duration of treatment ≥ 10 days, doses of more than 100 mg, intravenous administration and early initiation of therapy. Also, the use of corticosteroids in combination with anakinra appears to improve clinical outcome compared to monotherapy with anakinra.

  • Digital Image Colorimetry for Determination of Ethanol in Exhaled Breath Condensate

    by Yasaman Sefid-Sefidehkhan, Maryam Khoshkam, Samineh Raha, Fariba Pourkarim, Abolghasem Jouyban, Maryam Khoubnasabjafari, Vahid Jouyban-Gharamaleki, Elaheh Rahimpour

    Aim: This study aimed to develop a colorimetric approach for quantifying ethanol using smartphone image analysis. Method: This research presents a straightforward smartphone-based colorimetric sens...


  • Open Access

    Clinical considerations on monkeypox antiviral medications: An overview

    by Fariba Pourkarim, Taher Entezari‐Maleki

    Monkeypox (mpox), a virus belonging to the orthopoxvirus family, can cause a zoonotic infectious disease with morbidity and cosmetic complications. Therefore, effective antiviral drugs with appropriate safety profiles are important for the treatment of patients with mpox. To date, there is no FDA‐approved drug for the treatment of mpox. However, tecovirimat, brincidofovir, and cidofovir are the candidate therapies for the management of mpox. Given the safety concerns following the use of these medications, we aimed to review evidence on the clinical considerations of mpox antiviral medications that will be useful to guide clinicians in the treatment approach. Based on the current evidence, tecovirimat has favorable clinical efficacy, safety, and side effect profile and it can be considered as first‐line treatment for mpox.


  • Nasal Actinomyces in a 7-year-old Boy with Recurrent Nasal Bleeding: A Case Report

    by Mohammad Solduzian, Abbasali Hosseinpourfeizi, Amir Hossein Jafari-Rouhi, Fariba Pourkarim

  • Open Access

    Molnupiravir: A new candidate for COVID‐19 treatment

    by Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee

    The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnupiravir is an antiviral drug with anti‐RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients.


  • Solubilization Methods for Paclitaxel and Docetaxel: An Overview

    by Fariba Pourkarim, Elaheh Rahimpour, Sima Alvani, Abolghasem Jouyban

    Cancer is still a serious disease with high incidence over the past decades. Many anticancer drugs are discovered and used to treat cancer, among them, taxanes such as paclitaxel and docetaxel have high lipophilicity and low aqueous solubility which is further magnified considering the strong need for administering them by intravenous infusion. Currently, the poor water-solubility of taxanes is improved by prodrug formation, conjugation, inclusion complexation, micellar solubilization and liposome-based formulations. Recent achievement for solubilization of taxanes are reviewed and critically discussed regarding their pharmaceutical and chemical applications.


  • A Simple Colorimetric Method for Determination of Ethanol in Exhaled Breath Condensate

    by Fariba Pourkarim, Elaheh Rahimpour, Maryam Khoubnasabjafari, Vahid Jouyban-Gharamaleki, Sara Farhang, Abolghasem Jouyban

    Background: Ethanol is considered as a toxic compound when used in excess amounts. The toxic concentration for ethanol was reported to be 1000 – 2000 μg.mL-1 in plasma and serum samples. The aim of the current study was to develop a rapid and catalyst free colorimetric method for determination of ethanol in exhaled breath condensate (EBC) sample. Methods: A redox reaction with dichromate-based colorimetric method was used for determination of ethanol in EBC. Results: The proposed method shows a good sensitivity and selectivity for ethanol in compared with other compounds and biomarkers existing in EBC. The color change can be easily observed by the naked eye in the presence of ethanol in the range of 300 - 8000 μg.mL-1. The quantitative detection of ethanol was fully validated and used for determination of ethanol in EBC of alcohol administrated individuals. Conclusion: This catalyst free colorimetric method has great potential for ethanol determination owing to many desirable properties such as high reliability, high sensitivity, and fast response time.


  • Determination of Verapamil in Exhaled Breath Condensate by Using Microextraction and Liquid Chromatography

    by Fariba Pourkarim, Ali Shayanfar, Maryam Khoubnasabjafari, Fariborz Akbarzadeh, Sanaz Sajedi-Amin, Vahid Jouyban-Gharamaleki, Abolghasem Jouyban

    Background: Developing a simple analysis method for quantification of drug concentration is one of the essential issues in pharmacokinetic and therapeutic drug monitoring studies.Objective: A fast and reliable dispersive liquid-liquid microextraction procedure was employed for preconcentration of verapamil in exhaled breath condensate (EBC) samples and this was followed by the determination with high-performance liquid chromatography-ultraviolet detection.Methods: A reverse-phase high-performance liquid chromatography (RP-HPLC) combined with a dispersive liquid-liquid microextraction method (DLLME) was applied for quantification of verapamil in the EBC samples. The developed method was validated according to FDA guidelines.Results: Under the optimum conditions, the method provided a linear range between 0.07 and 0.8 µg.mL-1 with a coefficient of determination of 0.998. The intra- and inter-day relative standard deviation and relative error values of the method were below 15%, which indicated good precision and accuracy. The proposed method was successfully applied for the analysis of verapamil in two real samples with concentrations of 0.07 and 0.09 µg.mL-1.Conclusion: The established HPLC-UV-DLLME method could be applied for the analysis of verapamil in human EBC samples.


  • Solubility of acetaminophen in 1-propanol + water mixtures at T = 293.2–313.2 K

    by Fariba Pourkarim, Seyyedeh Narjes Mirheydari, Fleming Martinez, Abolghasem Jouyban

    The mole fraction solubilities of acetaminophen (ACP) were measured in the binary solvent mixtures of {1-propanol + water} at T = 293.2–313.2 K. The Jouyban–Acree, Jouyban–Acree–van’t Hoff, combined nearly ideal binary solvent/Redlich–Kister (CNIBS/R-K) and modified Wilson models as well as a non-linear model presented by Machatha et al. were used to correlate the measured equilibrium solubilities. Furthermore, the experimental data were predicted with five predictive models, i.e. Yalkowsky, extended Yalkowsky as well as trained versions of Yalkowsky, Jouyban–Acree and Jouyban–Acree–Hansen models. Moreover, the apparent standard molar Gibbs energy, enthalpy, and entropy of dissolution and mixing ( ΔGsoln∘, ΔHsoln∘, ΔSsoln∘, ΔGmix∘, ΔHmix∘, ΔSmix∘) of ACP in {1-propanol (1) + water (2)} mixtures were calculated at mean harmonic temperature Thm = 303 K based on van’t Hoff and Gibbs free energy equations. Additionally, preferential solvation parameters of ACP in the mixtures were also analysed based on the inverse Kirkwood–Buff integrals.